The (cost)effectiveness of paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients.

Trial Profile

The (cost)effectiveness of paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients.

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 24 Mar 2012

At a glance

  • Drugs Paricalcitol (Primary) ; Alfacalcidol
  • Indications Secondary hyperparathyroidism
  • Focus Therapeutic Use
  • Acronyms CEPS
  • Most Recent Events

    • 09 Aug 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top